Value of MRI Multi-sequence Scanning Combined with fPSA/tPSA in Differentiating Benign and Malignant Prostate Lesions

Jing SHI; Ning CHEN; Jianqiang GE

doi:10.12259/j.issn.2095-610X.S20250516

Volume 46 Issue 5

May 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(5): 133-140

Jing SHI, Ning CHEN, Jianqiang GE. Value of MRI Multi-sequence Scanning Combined with fPSA/tPSA in Differentiating Benign and Malignant Prostate Lesions[J]. Journal of Kunming Medical University, 2025, 46(5): 133-140. doi: 10.12259/j.issn.2095-610X.S20250516

Citation:

Jing SHI, Ning CHEN, Jianqiang GE. Value of MRI Multi-sequence Scanning Combined with fPSA/tPSA in Differentiating Benign and Malignant Prostate Lesions[J]. Journal of Kunming Medical University, 2025, 46(5): 133-140. doi: 10.12259/j.issn.2095-610X.S20250516

Citation:

PDF( 2241 KB)

Value of MRI Multi-sequence Scanning Combined with fPSA/tPSA in Differentiating Benign and Malignant Prostate Lesions

doi: 10.12259/j.issn.2095-610X.S20250516

The First Veterans Hospital of Hebei，Xingtai Hebei 054001，China

Received Date: 2025-02-20
Publish Date: 2025-05-30

Abstract

Abstract

Objective To analyze the qualitative efficacy of MRI multi-sequence scanning combined with fPSA/tPSA in benign and malignant prostate lesions. Methods A retrospective analysis was conducted on the clinical data of 118 patients with suspected prostate cancer who visited Hebei Provincial First Veterans Hospital from January 2021 to November 2023. All the patients underwent DWI and DCE-MRI examinations. They were divided into the benign group （n = 39） and the malignant group （n = 39） based on the pathological results of partial prostatectomy or ultrasound-guided prostate biopsy. The DWI parameters, DCE-MRI parameters, PI-RADS scores, and fPSA/tPSA of the two groups were compared to analyze the factors influencing benign and malignant prostate lesions. ROC curves were drawn to analyze the diagnostic value of each index for benign and malignant prostate lesions. Results Among 118 suspected prostate cancer patients, 118 lesions were detected through biopsy at our hospital or initial diagnosis at Hebei Provincial First Veterans Hospital followed by surgical and biopsy pathological examinations at external medical institutions. Of these lesions, 79 （66.95%） were malignant and 39 （33.05%） were benign; the Rmax and SImax of the malignant group were higher than those of the benign group, and the Tmax and ADC values were lower than those of the benign group （P < 0.05）; the PI- RADS scores were higher than the benign group, and fPSA/tPSA was lower than the benign group （P < 0.05）; Multivariate logistic regression analysis revealed that Rmax [OR: 1.374 （95%CI: 1.211～1.560）], SImax [OR: 6.849 （95%CI: 2.573～18.230）], and PI-RADS score [OR: 4.689 （95%CI: 2.646～8.309）] were the risk factors for malignant prostate lesions （P < 0.05）, while Tmax [OR: 0.906 （95%CI: 0.873～0.941）], ADC value [OR: 0.930 （95%CI: 0.905～0.955）], and fPSA/tPSA [OR: 0.859 （95%CI: 0.812～0.908）] were protective factors （P < 0.05）; the ROC curve revealed that the AUC （95%CI） of Rmax, SImax, Tmax, ADC value, fPSA/tPSA, and PI-RADS score for the diagnosis of benign and malignant prostate lesions were 0.827 （0.747～0.906）, 0.752 （0.660～0.844）, 0.851 （0.773～0.930）, 0.845 （0.765～0.925）, 0.813 （0.722～0.905）, 0.844 （0.768～0.920）, and 0.940 （0.883～0.997）. Conclusion DCE-MRI and DWI combined with PI-RADS score and fPSA/tPSA can improve the qualitative diagnostic accuracy of malignant prostate lesions, and provide reference for clinical identification of benign and malignant lesions.

FullText(HTML)

References(23)

References

[1]	Schaeffer E M, Srinivas S, Adra N, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2023,21(10):1067-1096. doi: 10.6004/jnccn.2023.0050
[2]	O'Shea A,Harisinghani M. PI-RADS: Multiparametric MRI in prostate cancer[J]. MAGMA,2022,35(4):523-532. doi: 10.1007/s10334-022-01019-1
[3]	Panebianco V, Villeirs G, Weinreb J C, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after Rradiation therapy and radical prostatectomy[J]. Eur Urol Oncol,2021,4(6):868-876. doi: 10.1016/j.euo.2021.01.003
[4]	Kachuri L,Hoffmann T J,Jiang Y,et al. Genetically adjusted PSA levels for prostate cancer screening[J]. Nat Med,2023,29(6):1412-1423. doi: 10.1038/s41591-023-02277-9
[5]	Mohsen N. Role of mri ultrasound, and computed tomography in the management of prostate cancer[J]. PET Clin,2022,17(4):565-583. doi: 10.1016/j.cpet.2022.07.002
[6]	Wang M,Qi J,George A K,et al. The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance[J]. Prostate,2022,82(10):1068-1074. doi: 10.1002/pros.24357
[7]	柯渺, 刘锦慧, 钟少楠, 等. 18F-AlF-P16-093 PET联合多参数MRI在前列腺癌原发灶诊断中的应用: 基于穿刺病理学的头对头研究[J]. 中华核医学与分子影像杂志,2024,44(9):533-538. doi: 10.3760/cma.j.cn321828-20240607-00199
[8]	陶忆杰,赵晓平,孙仁祥. 前列腺癌患者DCE-MRI,DWI影像表现及与PSA的关系[J]. 中国CT和MRI杂志,2024,22(6):127-129. doi: 10.3969/j.issn.1672-5131.2024.06.040
[9]	Weinreb J C, Barentsz J O, Choyke P L, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2[J]. Eur Urol,2016,69(1):16-40. doi: 10.1016/j.eururo.2015.08.052
[10]	杜竑兵,李海青,敬杰. 磁共振成像动态增强扫描联合T2WI及DWI序列对前列腺病变的诊断分析[J]. 中国性科学,2023,32(11):25-29. doi: 10.3969/j.issn.1672-1993.2023.11.007
[11]	杨晓芳,张智星,王军,等. 基于MRI的影像组学对PSA"灰区"且PI-RADS 3分及以上前列腺癌的诊断价值研究[J]. 临床放射学杂志,2023,42(6):953-959.
[12]	刘晓东,方习奇,唐桑,等. 动态对比增强MRI联合表观扩散系数值对前列腺中央区癌的诊断价值[J]. 实用放射学杂志,2020,36(4):599-602. doi: 10.3969/j.issn.1002-1671.2020.04.023
[13]	祝丽,孟婕,王欢欢,等. 多参数MRI联合影像组学在鉴别PI-RADS 4~5分前列腺病灶良恶性中的应用分析[J]. 磁共振成像,2024,15(4):93-98+119. doi: 10.12015/issn.1674-8034.2024.04.015
[14]	Scialpi M, Martorana E, Scialpi P, et al. S-PI-RADS and PI-RRADS for biparametric mri in the detection of prostate cancer and post-treatment local recurrence[J]. Anticancer Res,2023,43(1):297-303. doi: 10.21873/anticanres.16163
[15]	Schoots I G, Barentsz J O, Bittencourt L K, et al. PI-RADS committee position on mri without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review[J]. AJR Am J Roentgenol,2021,216(1):3-19. doi: 10.2214/AJR.20.24268
[16]	Wei J T, Barocas D, Carlsson S, et al. Early detection of prostate cancer: aua/suo guideline part i: Prostate cancer screening[J]. J Urol,2023,10(1):46-53.
[17]	Meunier M E, Neuzillet Y, Dreyfus J F, et al. PSA and obesity among men with localized prostate cancer: results of the androcan study[J]. World J Urol,2021,39(8):2945-2951. doi: 10.1007/s00345-020-03557-6
[18]	Christensson A,Björk T,Nilsson O,et al. Serum prostate specific antigen complexed to α 1-antichymotrypsin as an indicator of prostate cancer[J]. The Journal of Urology,1993,150(1):100-105. doi: 10.1016/S0022-5347(17)35408-3
[19]	王兴林,敬杰,李海青,等. 3.0T磁共振小视野IVIM-DWI联合血清fPSA/tPSA鉴别诊断前列腺癌的应用评价[J]. 中国CT和MRI杂志,2023,21(10):142-145. doi: 10.3969/j.issn.1672-5131.2023.10.044
[20]	胡亚萍,黄晓莹,张婷玉,等. PI-RADS联合fPSA/tPSA诊断前列腺癌的应用价值[J]. 医学影像学杂志,2020,30(1):104-107.
[21]	Nakanishi K, Tanaka J, Nakaya Y, et al. Whole-body mri: detecting bone metastases from prostate cancer[J]. Jpn J Radiol,2022,40(3):229-244. doi: 10.1007/s11604-021-01205-6
[22]	Würnschimmel C,Chandrasekar T,Hahn L,et al. MRI as a screening tool for prostate cancer: current evidence and future challenges[J]. World J Urol,2023,41(4):921-928.
[23]	李磊,桂赞龙,程华根,王传圣. DCE-MRI和ADC值对前列腺良恶性病变的鉴别及ADC值与血清TPSA的关系[J]. 实用放射学杂志,2022,38(4):612-615. doi: 10.3969/j.issn.1002-1671.2022.04.024

Relative Articles(20)

Relative Articles

[1]	Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208
[2]	Yun LIU, Hong-bing HE. The Research Progress on the Effect of Prostaglandin E2 on Bone Remodeling. Journal of Kunming Medical University, 2021, 42(9): 149-155. doi: 10.12259/j.issn.2095-610X.S20210916
[3]	Shen Jie , Guan Run Yun , He Zong Hai , Zheng Ming Xing . Comparison of the Efficacy and Complications of PKRP and TmLRP in Treatment of Early Benigh Prostate Hyperplasia. Journal of Kunming Medical University, 2017, 38(06): 77-81.
[4]	Wang Hong . Role of Prostaglandin E2 in the Pathogenesis of COPD with Lung Cancer. Journal of Kunming Medical University,
[5]	Wang Yang . Comparison of Short-term Efficacy between Transurethral Plasmakinetic Enucleation and Holmium Laser Enucleation in the Treatment of Benign Prostatic Hyperplasia. Journal of Kunming Medical University,
[6]	Li Xiao Tao . . Journal of Kunming Medical University,
[7]	Zhang He Yun . . Journal of Kunming Medical University,
[8]	Dong Zi Ping . . Journal of Kunming Medical University,
[9]	Zhang Jing Song . . Journal of Kunming Medical University,
[10]	Guo Wei . . Journal of Kunming Medical University,
[11]	Hao Jin Gang . . Journal of Kunming Medical University,
[12]	Shen Hong . . Journal of Kunming Medical University,
[13]	Zhang Wei . . Journal of Kunming Medical University,
[14]	Liu Jin Hong . . Journal of Kunming Medical University,
[15]	Di Yu Qiang . . Journal of Kunming Medical University,
[16]	Li Yi . . Journal of Kunming Medical University,
[17]	. . Journal of Kunming Medical University,
[18]	. . Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	Ruan Dian Sheng . . Journal of Kunming Medical University,